阻塞性睡眠呼吸暂停低通气综合征合并代谢综合征的患病情况及影响因素分析OA

Objective To investigate the prevalence of obstructive sleep apnea-hypopnea syndrome(OSAHS)combined with metabolic syndrome(MS),and analyze the related factors affecting OSAHS combined with MS.Methods Totally 290 patients with OSAHS hospitalized in the First Affiliated Hospital of Baotou Medical College and diagnosed as OSAHS were collected from August 2020 to October 2022.According to whether the patients were complicated with MS,they were divided into OSAHS combined with MS group and simple OSAHS group.According to apnea hypopnea index(AHI),the patients of OSAHS combined with MS group were divided into three subgroups:mild group,moderate group and severe group.The general condition,biochemical indicators and sleep parameters of patients were recorded,and the relevant factors affecting OSAHS with MS were determined by logistic regression analysis.Results(1)Among the 290 patients with OSAHS,the incidence of MS was 51.7%,male patients were more than female patients,and the peak of OSASH with MS was between 50 and 59 years old.(2)body mass index(BMI),systolic blood pressure,hypertension history,diabetes history,AHI,fasting blood glucose(FBG),triglyceride(TG),high density lipoprotein-cholesterol(HDL-C),uric acid(UA)were statistically different between the two groups(P<0.05);Logistic regression analysis showed that BMI,FBG,TG,HDL-C,UA,history of hypertension and history of diabetes were independent risk factors for OSAHS with MS(P<0.05).(3)There were statistically significant differences in gender,age,BMI,AHI,TG,HDL-C and UA among the three groups of OSAHS with MS with different severity(P<0.05).Logistic regression analysis showed that BMI,TG and HDL-C were independent risk factors affecting OSAHS with MS with different severity(P<0.05).Conclusion(1)The inpatients with OSAHS have a high incidence of MS.(2)OSAHS combined with MS is related to BMI,blood pressure,blood glucose,blood lipid,blood uric acid level and other factors.(3)Overweight and dyslipidemia play an important role in the process of inducing disease aggravation.